AnaptysBio, Inc. Common Stock (ANAB) Stock
Key stats
- Market cap
- $1.46B
- Price / Earnings ratio
- 7.4x
- EPS (TTM)
- $6.76
- Volume
- Loading
- 52-week high
- $73.30
- 52-week low
- $32.20
Source: third-party data provider, as of November 13, 2026
Compare with ANAB
Recent news
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
ANAB
Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed
Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed
ANAB
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
ANAB
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
ANABNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 51.17
- MACD 12/26/9
- -0.53
- EMA 9 of MACD
- -0.76
- MACD histogram
- 0.24
- SMA 50
- $50.18
- Price below SMA 50
- EMA 50
- $50.01
- Price below EMA 50
- SMA 200
- $56.51
- Price below SMA 200
- EMA 200
- $52.94
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
ANABWhy This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed
Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed
ANABAnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
ANABGSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
ANAB
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
ANAB
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
ANAB
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
ANAB
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
ANAB
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?
ANAB
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
ANABNews tone: automated (AI) classification of the article's content, not a price prediction.
About AnaptysBio, Inc. Common Stock
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel R. Faga | President, CEO & Director | 1980 |
| Mr. Christopher M. Murphy | Chief Financial Officer | 1984 |
| Ms. Beth Mueller | Senior Vice President of Human Resources | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.17
- MACD 12/26/9
- -0.53
- EMA 9 of MACD
- -0.76
- MACD histogram
- 0.24
- SMA 50
- $50.18
- Price below SMA 50
- EMA 50
- $50.01
- Price below EMA 50
- SMA 200
- $56.51
- Price below SMA 200
- EMA 200
- $52.94
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $60.00
- Average
- $76.50
- High
- $95.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.6 | +11.3 | ||||||||||
| 2022 | -11.0 | -4.1 | -18.2 | -6.6 | -21.0 | +7.4 | +2.3 | +14.5 | +3.0 | +11.4 | -6.7 | +13.6 |
| 2023 | -14.8 | -0.2 | -13.4 | -5.7 | -9.8 | +10.1 | +0.5 | -4.3 | -8.8 | -7.5 | -14.5 | +42.8 |
| 2024 | +8.8 | +5.3 | -11.5 | +14.2 | -8.0 | +6.8 | +41.6 | +11.8 | -7.2 | -37.9 | +15.1 | -45.7 |
| 2025 | +34.2 | +1.0 | +27.0 | +20.8 | +2.4 | +1.6 | +8.4 | -17.7 | +48.6 | +14.4 | +15.6 | +17.4 |
| 2026 | +5.5 | +8.9 | +1.0 | +15.9 | -16.6 | +27.0 | -18.4 | +6.3 | -9.1 | -0.7 | +4.0 |
